Cornea squamous cell carcinoma

Summary

Cornea squamous cell carcinoma (MONDO:0001740) is a cancer. A subtype of eye carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	cornea squamous cell carcinoma
Mondo ID	MONDO:0001740
DOID	DOID:13538
NCIT	C4552
SNOMED CT	255008003
UMLS	C0346366
MedGen	91102
GARD	0022999
Anatomy (UBERON)	UBERON:0000964
Is cancer (heuristic)	yes

Also known as: cornea epidermoid carcinoma · cornea squamous cell carcinoma · corneal epidermoid carcinoma · corneal squamous cell carcinoma · epidermoid carcinoma of cornea · epidermoid carcinoma of the cornea · squamous cell carcinoma of cornea · squamous cell carcinoma of the cornea

Disease family

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › head and neck carcinoma › eye carcinoma › cornea squamous cell carcinoma

Related subtypes (8): lacrimal gland carcinoma, eyelid carcinoma, eye carcinoma in situ, conjunctival squamous cell carcinoma, ocular sebaceous carcinoma, aniridia 2, aniridia 3, PAX6-related ocular dysgenesis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.